Citadel Advisors LLC Exits Position in Acrivon Therapeutics, Inc. (ACRV)

This Schedule 13G/A filing, dated May 15, 2026, indicates that Citadel Advisors LLC and its affiliated reporting persons, including Kenneth Griffin, have effectively exited their position in Acrivon Therapeutics, Inc. (ACRV). As of the event date on March 31, 2026, the reporting group's beneficial ownership has been reduced to a nominal 13 shares, representing 0.0% of the company's outstanding common stock. This is an amendment to a previous filing, signaling that the group no longer holds a significant stake in the issuer. The reporting persons involved include Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC. The filing confirms that the securities were not held for the purpose of influencing or changing the control of the issuer. The 13 shares remaining are attributed specifically to Citadel Securities LLC and its controlling entities, while Citadel Advisors LLC reported zero shares.